BILL ANALYSIS Ó
ACR 128
Page 1
ASSEMBLY THIRD READING
ACR
128 (Brown)
As Amended June 27, 2016
Majority vote
------------------------------------------------------------------
|Committee |Votes|Ayes |Noes |
| | | | |
| | | | |
| | | | |
|----------------+-----+----------------------+--------------------|
|Transportation |16-0 |Frazier, Linder, | |
| | |Baker, Bloom, Brown, | |
| | |Chu, Daly, Dodd, | |
| | |Eduardo Garcia, | |
| | |Gomez, Kim, Mathis, | |
| | |Medina, Melendez, | |
| | |Nazarian, O'Donnell | |
| | | | |
|----------------+-----+----------------------+--------------------|
|Rules |9-0 |Gordon, Chang, | |
| | |Arambula, Brough, | |
| | |Holden, Jones, Quirk, | |
| | |Rodriguez, Waldron | |
| | | | |
| | | | |
------------------------------------------------------------------
SUMMARY: Recognizes the month of September 2016 as Sickle Cell
Anemia Awareness Month. Specifically, this resolution makes the
ACR 128
Page 2
following legislative findings:
1)Sickle cell anemia and sickle cell disease refer to a group of
inherited disorders that affect red blood cells causing the
person's body to produce abnormally shaped red blood cells
that resemble a crescent or sickle of which do not last as
long as round blood cells, causing anemia.
2)It is estimated that more than 90,000 Americans have sickle
cell anemia; one in every 500 African Americans and one in
every 36,000 Latino births are affected.
3)Sickle cell anemia can be a life-threatening condition, and
access to comprehensive care can be limited by social,
economic, cultural, and geographic barriers; and the average
cost of hospitalization for sickle cell anemia in 2004 was
$6,223 and the total cost for 84,000 hospital admissions was
$488,000,000; of which 65% was covered by Medicaid funds.
4)In 1972, the Sickle Cell Anemia Control Act was signed into
law by President Richard Nixon after pledging that his
administration would "reverse the record of neglect of the
dreaded disease" by increasing funding for and expanding
sickle cell anemia-related programs, including the development
of comprehensive sickle cell anemia centers.
5)A potentially groundbreaking investigational drug, GMI 1070,
designed to treat painful vaso-occlusive crises, which occur
when red blood cells lump together and impede blood flow in
sickle cell patients, has been found to be safe following
clinical trials at the University of California, Davis.
FISCAL EFFECT: None
ACR 128
Page 3
Analysis Prepared by:
Nicole Willis / RLS. / (916) 319-2800 FN:
0003802